Drug Profile


Alternative Names: Cerdelga; Eliglustat tartrate; Genz-112638

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator University of Michigan
  • Developer Sanofi Genzyme
  • Class 2 ring heterocyclic compounds; Amides; Pyrrolidines; Small molecules
  • Mechanism of Action Glucosylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gaucher's disease type I

Most Recent Events

  • 01 Dec 2016 Sanofi completes a phase I pharmacokinetics trial for Gaucher Disease in USA (NCT02536911)
  • 08 Mar 2016 Biomarkers information updated
  • 21 Jan 2016 Genzyme completes the phase III ENGAGE trial in Gaucher's disease type I in USA, Bulgaria, Canada, Colombia, India, Israel, Jordan, Lebanon, Mexico, Netherlands, Russia, Serbia, Tunisia and United Kingdom (NCT00891202)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top